MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
Advertisement
Episode 3 of the MS Compass: Guiding Clinical Care® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
MS Compass: Guiding Clinical Care is a NeurologyLive podcast led by Lindsay Ross, MD, a board-certified neurologist specializing in multiple sclerosis and neuroimmunology at the Cleveland Clinic’s Mellen Center. The series centers on the unique clinical considerations facing women with MS, from emerging research and evolving treatment strategies to gaps in care that are gaining renewed attention. Through conversations with expert guests across neurology and related disciplines, Ross examines how science, advocacy, and real-world practice are shaping the next era of MS care for women.
In this episode, host Lindsay Ross, MD, is joined by joined by Rachel Galioto, PhD, a Cleveland Clinic neuropsychologist focused on neuroimmunology, to explore how clinicians can better recognize, assess, and manage cognitive concerns in people with MS.
Galioto discusses evolving evidence suggesting that the cognitive profile of MS may be changing in the modern treatment era, with memory and language difficulties potentially playing a greater role than historically appreciated. Ross and Galioto also examine how disease burden, sleep, mood, medications, pain, and other secondary factors can interact to affect cognition, emphasizing that cognitive dysfunction is rarely attributable to a single cause. The conversation concludes with practical guidance on medication review, addressing sleep problems, determining when formal neuropsychological testing is worthwhile, and using cognitive rehabilitation and compensatory strategies to reduce the impact of cognitive difficulties on everyday life.
EPISODE BREAKDOWN
0:00 – Introduction to cognitive dysfunction in MS and its impact on patients
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
